Our HTGF Portfolio of startups offers excellent opportunities and is always hiring talented people.
Locations
Basel City, Switzerland · Basel-Landschaft, Switzerland
industry
Pharmaceuticals
Size
51-200 employees
founded in
2019
Alentis Therapeutics, the Claudin-1 (CLDN1) company, is a clinical stage biotechnology company on a mission to develop first-in-class antibodies and ADCs for CLDN1+ tumors and organ fibrosis. Alentis is pioneering a novel approach to modify and reverse the course of disease progression targeting CLDN1, a previously unexploited target that plays a key role in the pathology of tumors and fibrotic diseases across multiple organs. Alentis is the only company developing potential treatments for solid cancers and fibrosis targeting CLDN1. Alentis’ portfolio of anti-CLDN1 monoclonal antibodies includes a novel class of anti-cancer therapies designed to reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is highly promising for drug development as many cancers use the TME to build barriers that shield against immune system attacks. Alentis’ lead oncology asset, ALE.C04, is the first potential treatment to target CLDN1.
Something looks off?